Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TG Therapeutics, Inc. - Common Stock (NQ:TGTX)

47.94 -1.56 (-3.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,769,549
Open 49.70
Bid (Size) 47.50 (1,500)
Ask (Size) 47.90 (300)
Prev. Close 49.50
Today's Range 47.53 - 49.70
52wk Range 26.05 - 59.30
Shares Outstanding 154,420,772
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
TG Therapeutics (TGTX) Q2 2026 Earnings Call Transcript ↗
BRIUMVI revenue surged 64% year-over-year as patient starts hit record levels. 
Via The Motley Fool
Topics Earnings
News headline image
TG Therapeutics Q2 Earnings Call Highlights ↗
TG Therapeutics (NASDAQ:TGTX) reported second-quarter 2026 revenue of $240 million and raised its full-year sales outlook for BRIUMVI, its treatment for relapsing multiple sclerosis, as the company... 
Via MarketBeat
Topics Earnings

Performance

YTD
+63.7%
+63.7%
1 Month
-12.9%
-12.9%
3 Month
+12.4%
+12.4%
6 Month
+66.3%
+66.3%
1 Year
+76.8%
+76.8%

More News

Read More
TG Therapeutics (NASDAQ:TGTX) Falls as Q2 Revenue Beats but EPS Misses, Guidance Raised Below Estimates ↗
Via Chartmill
TG Therapeutics (NASDAQ:TGTX) Meets Minervini's Trend Template with Accelerating Growth ↗
Via Chartmill
News headline image
2 Fast-Growing Pharmaceutical Stocks to Buy Now ↗
Via The Motley Fool
TG THERAPEUTICS INC (NASDAQ:TGTX): High-Growth Momentum Meets Minervini Trend Template Technical Strength ↗
Via Chartmill
TG THERAPEUTICS INC (NASDAQ:TGTX) Screens as Affordable Growth Play with Strong Revenue Surge and Discounted Valuation ↗
Via Chartmill
The Quest to Repair What Multiple Sclerosis Takes Away
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis
Via Investor Brand Network
News headline image
TG Therapeutics Stock Surges After Drug Trial Update ↗
Via Benzinga
News headline image
Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More ↗
Via The Motley Fool
Topics Regulatory Compliance
TG Therapeutics (NASDAQ:TGTX) Q1 2026 Earnings Beat Revenue Guidance but Miss EPS Estimates ↗
Via Chartmill
Topics Earnings
TG Therapeutics Inc (NASDAQ:TGTX) Shows Strong Growth and Technical Setup for Potential Upside ↗
Via Chartmill
News headline image
The Quest to Repair What Multiple Sclerosis Takes Away
From BioMedWire
Via GlobeNewswire
News headline image
Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position ↗
Via The Motley Fool
Topics Regulatory Compliance
TG Therapeutics Inc (NASDAQ:TGTX): An Affordable Growth Stock with Strong Momentum ↗
Via Chartmill
TG Therapeutics Inc (NASDAQ:TGTX) Presents a Compelling Momentum Case with Strong Growth and Technical Setup ↗
Via Chartmill
News headline image
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug ↗
Via The Motley Fool
News headline image
TG Therapeutics (TGTX) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
TGTX Q1 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
TG THERAPEUTICS INC (NASDAQ:TGTX) Q4 2025 Earnings Miss Estimates Despite Strong BRIUMVI Outlook ↗
Via Chartmill
Topics Earnings
News headline image
What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investment ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop ↗
Via The Motley Fool
News headline image
TG Therapeutics (TGTX) Q4 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
Soleus Adds a Significant Number of Celcuity Shares ↗
Via The Motley Fool

Frequently Asked Questions

Is TG Therapeutics, Inc. - Common Stock publicly traded?
Yes, TG Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does TG Therapeutics, Inc. - Common Stock trade on?
TG Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for TG Therapeutics, Inc. - Common Stock?
The ticker symbol for TG Therapeutics, Inc. - Common Stock is TGTX on the Nasdaq Stock Market
What is the current price of TG Therapeutics, Inc. - Common Stock?
The current price of TG Therapeutics, Inc. - Common Stock is 47.94
When was TG Therapeutics, Inc. - Common Stock last traded?
The last trade of TG Therapeutics, Inc. - Common Stock was at 08/13/26 04:00 PM ET
What is the market capitalization of TG Therapeutics, Inc. - Common Stock?
The market capitalization of TG Therapeutics, Inc. - Common Stock is 7.40B
How many shares of TG Therapeutics, Inc. - Common Stock are outstanding?
TG Therapeutics, Inc. - Common Stock has 7B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.